Reuters

BridgeBio plans to price the therapy at $18,759.12 for a 28-day supply

Improvement in overall survival was one of the study's dual main goals, according to Merck and Eisai

Y-mAbs said it is assessing the implications of the Food and Drug Administration's (FDA) Complete Response Letter (CRL) and the…

The drug's efficacy as a treatment for ulcerative colitis is currently being assessed in a mid-stage study

BioNTech, said the facility, which will also double as its regional headquarters, will initially be used to make a range of…

The Swiss drugmaker conducted two identically designed studies, each with about 1,000 participants, who were examined and queried…

The company now expects annual revenue to be near the low end of its prior forecast range of between $2 billion and $2.3 billion

The long-acting therapy, also known as nirsevimab, was given the European Union (EU) marketing authorisation for the prevention of…

The company has been on an acquisition spree in recent months, from buying supplement maker Endura Mass to stake purchases in…

The company did say the 2023 outlook excludes expected contracts with countries such as the US and Japan, and that it anticipated…